NASDAQ · MIST
Healthcare · Biotechnology
$1.21
Up+$0.03 (+2.54%)
Updated Sep 4, 2026, 10:50 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MIST does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning MIST.
MIST research
Company profile and research snapshot.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Cantor Fitzgerald | Overweight | — |
| May 14, 2026 | Wells Fargo | Overweight | — |
| Jan 6, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | Wells Fargo | Overweight | — |
| Dec 15, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study
Benzinga · Aug 20, 2026
Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.
Benzinga · Aug 20, 2026
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.
SeekingAlpha · Aug 18, 2026
CARDAMYST is expensive with no proven advantage over cheap generics, and Milestone faces heavy debt and ongoing losses. Read why MIST stock is a Sell.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MIST.
